Akebia Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AKBA Nasdaq 2834 www.akebia.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akebia Therapeutics, Inc.

Akebia Therapeutics Q1 Earnings Call Highlights - May 7th, 2026 7:22 am
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates - May 7th, 2026 6:50 am
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights - May 7th, 2026 5:00 am
United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates - May 6th, 2026 5:45 am
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 4th, 2026 2:05 pm
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology - May 4th, 2026 6:00 am
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights - Apr 30th, 2026 2:05 pm
Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards? - Apr 30th, 2026 1:10 pm
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates - Apr 29th, 2026 6:25 am
Are Options Traders Betting on a Big Move in Akebia Therapeutics Stock? - Apr 28th, 2026 6:36 am
New Strong Sell Stocks for April 28th - Apr 28th, 2026 2:00 am
Germany Anemia Treatment Market Forecast and Company Analysis Report 2026-2034 Featuring Akebia Therapeutics, GSK, Vertex, Pfizer, Sanofi, Takeda, Novartis, Johnson & Johnson, Roche, Biocon Biologics - Apr 24th, 2026 7:04 am
Akebia Therapeutics Leads The Pack Of 3 Promising Penny Stocks - Apr 13th, 2026 6:05 am
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 - Apr 13th, 2026 6:00 am
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium - Apr 7th, 2026 6:00 am
How The Akebia Therapeutics (AKBA) Narrative Is Shifting After Vafseo Revenue And Protocol Updates - Apr 6th, 2026 1:08 am
Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets - Apr 2nd, 2026 10:04 am
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors - Apr 1st, 2026 2:05 pm
Guardian Pharmacy (GRDN) Soars 9.1%: Is Further Upside Left in the Stock? - Mar 31st, 2026 3:32 am
Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy - Mar 31st, 2026 1:19 am